Protalix Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Protalix Biotherapeutics
PLX Stock  USD 2.04  0.01  0.49%   
Protalix Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Protalix Biotherapeutics' valuation are provided below:
Gross Profit
35.6 M
Profit Margin
0.0872
Market Capitalization
164.9 M
Enterprise Value Revenue
2.3103
Revenue
61.8 M
We have found one hundred twenty available trending fundamental ratios for Protalix Biotherapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protalix Biotherapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 1.2 B in 2026, whereas Market Cap is likely to drop slightly above 72.5 M in 2026.

Protalix Biotherapeutics Total Revenue

64.48 Million

Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 49.3 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.79, Dividend Yield of 0.0 or PTB Ratio of 3.45. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Protalix Stock
Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Protalix Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets52.1 M84.4 M69.4 M
Pretty Stable
Total Current Liabilities20.5 M29.5 M31.6 M
Slightly volatile
Cash31.4 M22.7 M37.6 M
Slightly volatile
Non Current Assets Total9.8 M15.3 M12.1 M
Very volatile
Cash And Short Term Investments33.8 M40.1 M42.4 M
Pretty Stable
Net Receivables2.9 M3.3 M2.9 M
Slightly volatile
Common Stock Shares Outstanding97.9 M93.2 M33.8 M
Slightly volatile
Liabilities And Stockholders Equity52.1 M84.4 M69.4 M
Pretty Stable
Non Current Liabilities Total5 M5.3 M47 M
Slightly volatile
Other Current Assets1.6 M986.4 K2.1 M
Slightly volatile
Total Liabilities55.3 M34.7 M80.3 M
Slightly volatile
Total Current Assets43.3 M69.1 M57.3 M
Pretty Stable
Short and Long Term Debt Total4.7 M5 M44.9 M
Slightly volatile
Property Plant And Equipment Net10.5 M11.5 M10.4 M
Very volatile
Non Currrent Assets Other504.7 K531.3 K2.4 M
Slightly volatile
Common Stock Total Equity62.7 K40.2 K69.1 K
Slightly volatile
Other Stockholder Equity509 M484.8 M314.9 M
Slightly volatile
Common Stock63.6 K87.4 K78.4 K
Very volatile
Accounts Payable4.1 M5.2 M5.4 M
Very volatile
Short Term Investments18.2 M17.3 M8.2 M
Slightly volatile
Other Assets4 M3.8 M1.7 M
Slightly volatile
Other Liabilities1.4 M1.5 M18.8 M
Slightly volatile
Property Plant Equipment8.2 M9 M9.9 M
Pretty Stable
Current Deferred Revenue3.1 M3.3 M7.6 M
Pretty Stable
Inventory25.7 M24.4 M11.4 M
Slightly volatile
Capital Surpluse298.9 M484.8 M278.4 M
Slightly volatile
Non Current Liabilities Other43.6 K45.9 K28.3 M
Slightly volatile
Short and Long Term Debt34.9 M18.2 M39.3 M
Slightly volatile
Deferred Long Term Asset Charges101.6 K101.7 K118.3 K
Slightly volatile
Property Plant And Equipment Gross55.3 M52.6 M22.8 M
Slightly volatile
Cash And Equivalents22.5 M17.8 M36.6 M
Slightly volatile
Capital Stock51.1 K68.4 K103 K
Slightly volatile
Capital Lease Obligations4.5 M5 M5.6 M
Slightly volatile

Protalix Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative49.3 M46.9 M15.1 M
Slightly volatile
Other Operating Expenses32.3 M56.9 M46.4 M
Slightly volatile
Total Operating Expenses25 M28.9 M34.5 M
Pretty Stable
Depreciation And Amortization1.6 M1.5 M1.9 M
Slightly volatile
Total Revenue64.5 M61.4 M35 M
Slightly volatile
Gross Profit35.1 M33.4 M21.3 M
Slightly volatile
Cost Of Revenue29.4 M28 M13.3 M
Slightly volatile
Research Development27 M14.9 M26.3 M
Very volatile
Selling And Marketing Expenses64 M60.9 M21.6 M
Slightly volatile
Extraordinary Items29.6 K33.3 K36.3 K
Slightly volatile
Interest Income768.8 K1.5 M711 K
Slightly volatile
Reconciled Depreciation1.1 M1.2 M1.6 M
Slightly volatile

Protalix Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow30.8 M27.2 M38.7 M
Pretty Stable
End Period Cash Flow31.4 M22.7 M37.6 M
Slightly volatile
Depreciation2 M1.5 M2 M
Slightly volatile
Stock Based Compensation2.3 M2.9 M2.4 M
Pretty Stable
Issuance Of Capital Stock3.1 M3.3 M35.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.792.9472.9603
Slightly volatile
Days Sales Outstanding21.7222.8733.9354
Slightly volatile
Average Payables45.2 K47.6 K49.2 K
Slightly volatile
Stock Based Compensation To Revenue0.06660.07011.4439
Slightly volatile
Capex To Depreciation1.211.130.7182
Slightly volatile
EV To Sales2.52.6372.7311
Slightly volatile
Inventory Turnover1.81.321.6283
Slightly volatile
Days Of Inventory On Hand501367453
Very volatile
Payables Turnover5.074.832.8818
Slightly volatile
Research And Ddevelopement To Revenue0.270.282.7338
Slightly volatile
Capex To Revenue0.02620.02760.0828
Slightly volatile
Cash Per Share0.520.551.475
Slightly volatile
Days Payables Outstanding74.3378.24317
Slightly volatile
Current Ratio2.562.77.6103
Slightly volatile
Receivables Turnover17.3516.5213.3288
Slightly volatile
Graham Number1.170.851.1575
Slightly volatile
Capex Per Share0.01930.02030.0559
Slightly volatile
Revenue Per Share0.80.852.1711
Slightly volatile
Interest Debt Per Share0.07770.08171.2609
Very volatile
Debt To Assets0.06440.06770.5717
Slightly volatile
Operating Cycle370390471
Very volatile
Days Of Payables Outstanding74.3378.24317
Slightly volatile
Quick Ratio1.661.747.2268
Slightly volatile
Cash Ratio0.840.892.0715
Slightly volatile
Days Of Inventory Outstanding501367453
Very volatile
Days Of Sales Outstanding21.7222.8733.9354
Slightly volatile
Fixed Asset Turnover5.044.83.8216
Slightly volatile
Debt Ratio0.06440.06770.5717
Slightly volatile
Price Sales Ratio2.792.9472.9603
Slightly volatile
Asset Turnover0.590.840.5897
Pretty Stable
Gross Profit Margin0.510.490.5289
Slightly volatile

Protalix Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap72.5 M76.4 M648.4 M
Slightly volatile
Enterprise Value1.2 B867.5 M1.2 B
Slightly volatile

Protalix Fundamental Market Drivers

Forward Price Earnings11.655
Cash And Short Term Investments34.8 M

Protalix Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.3 M3.1 M
Total Revenue61.4 M64.5 M
Cost Of Revenue28 M29.4 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue(0.33)(0.31)
Research And Ddevelopement To Revenue 0.28  0.27 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.85  0.80 
Ebit Per Revenue 0.07  0.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY